Sera Prognostics, Inc. SERA
1.93 USD -0.06 (-3.02%)
At closeNov 4, 2026, 8:47 AM EST
2.04 +0.11 +5.70%
Pre-market · Nov 4, 8:47 AM ET
1.93 Day range 2.05
1.56 52-week range 3.85
- YTD
- -34.58%
- 1 year
- -39.69%
- Market cap
- 76.14M
- Revenue (ttm)
- 94.00K
- EPS (ttm)
- -0.66
- Shares out
- 32.80M
- Forward P/E
- -16.23
- YTD return
- -34.58%
- 1-year return
- -39.69%
- Volume
- 14.95K
- Avg volume
- 22.06K
- Open
- 1.96
- Previous close
- 1.99
- Day's range
- 1.93 – 2.05
- 52-week range
- 1.56 – 3.85
- Beta
- 1.04
- Earnings date
- Aug 7, 2024
2Y -6.00 (-75.47%)
Key statistics
- Enterprise value
- 247.87M
- PEG ratio
- 0.00
- Price / sales
- 3089.82
- Price / book
- 5.31
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -31.00%
- Free cash flow
- -5.26M
- Total cash
- 49.75M
- Total debt
- 1.10M
- Return on equity
- -49.58%
- Short % of float
- 3.13%
- 50-day average
- 7.31
- 200-day average
- 7.94
Analyst view
Price target (mean) —
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 7, 2024
Expected Aug 7, 2024. Consensus EPS estimate -0.24.
Financials — quick view
SERA Revenue — quarterly 30.00K
SERA Net income — quarterly -9.14M
SERA EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.22 | -0.24 | -0.02 | -9.09% |
| Aug 7, 2024 | Jun 1, 2024 | -0.23 | — | — | — |
| Aug 7, 2024 | Jun 1, 2024 | -0.23 | -0.25 | -0.02 | -8.70% |
| May 8, 2024 | Mar 1, 2024 | -0.23 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.23 | -0.25 | -0.02 | -8.70% |
| Mar 20, 2024 | Dec 1, 2023 | -0.25 | -0.25 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 10, 2023 | Citigroup | main | Neutral | Neutral |
| Nov 10, 2022 | Citigroup | main | — | Neutral |
| Aug 29, 2022 | Oppenheimer | main | — | Outperform |
| Apr 27, 2022 | Berenberg | init | — | Buy |
| Mar 30, 2022 | Citigroup | down | Buy | Neutral |
| Nov 19, 2021 | Oppenheimer | init | — | Outperform |
About Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- seraprognostics.com
News
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Sera Prognostics Q2 EPS $(0.18) Misses $(0.15) Estimate, Sales $30.000K Miss $57.500K Estimate 
Sera Prognostics Announces Publication Of New Subgroup Analysis From PRIME Randomized Controlled Trial, Highlighting Screening Efficiency And Potential Cost Savings In Large Underserved Population 
Sera Prognostics To Participate In A Multi-institutional Research Program That Was Awarded Up To $10.4M By The Advanced Research Projects Agency For Health To Develop A Novel Point-of-care Diagnostic Test Designed To Improve The Safety Of Labor And Delivery 
Craig-Hallum Initiates Coverage On Sera Prognostics with Buy Rating, Announces Price Target of $6 
Earnings Scheduled For May 6, 2026 - Sera Prognostics Q1 EPS $(0.17), Inline, Sales $14.000K Miss $80.000K Estimate
Sera Prognostics Q4 EPS $(0.16) Beats $(0.18) Estimate, Sales $10.000K Miss $30.000K Estimate - Earnings Scheduled For March 18, 2026
- Earnings Scheduled For November 13, 2025
Your note
Sign in to keep a note on SERA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AERTS AUSTIN | Chief Financial Officer | Sale | Dec 9, 2024 | 285,756 |
| BONIFACE JOHN J | Officer | Sale | Nov 10, 2024 | 125,120 |
| CRITCHFIELD GREGORY C | Director | Stock Award(Grant) | Jun 5, 2024 | 807,270 |
| HARRISON ROBERT GARDNER | Chief Technology Officer | Sale | Nov 10, 2024 | 131,046 |
| JACKSON BENJAMIN R | General Counsel | Sale | Nov 10, 2024 | 135,528 |
| KEARNEY PAUL | Officer | Sale | Nov 10, 2024 | 176,889 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 16.57% | 5,434,399 | 46.74M | Sep 29, 2024 |
| RA Capital Management, L.P. | 9.25% | 3,032,808 | 26.08M | Sep 29, 2024 |
| Vivo Capital, LLC | 5.03% | 1,650,440 | 14.19M | Sep 29, 2024 |
| Blackrock Inc. | 4.70% | 1,540,281 | 13.25M | Sep 29, 2024 |
| Vanguard Group Inc | 3.66% | 1,199,509 | 10.32M | Sep 29, 2024 |
| JP Morgan Chase & Company | 2.70% | 884,867 | 7.61M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 2.13% | 697,621 | 6.00M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.09% | 684,412 | 5.89M | Sep 29, 2024 |
| Invesco ETF Tr II-Invesco Dorsey Wright SmallCap Momentum ETF | 1.76% | 578,726 | 4.98M | Sep 29, 2024 |
| JP Morgan U.S. Small Company Fund | 1.04% | 341,523 | 2.94M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.86% | 283,082 | 2.43M | Aug 30, 2024 |
| Vanguard Extended Market Index Fund | 0.85% | 279,223 | 2.40M | Sep 29, 2024 |